Research programme: mesenchymal stem cells therapeutics - Mesoblast

Drug Profile

Research programme: mesenchymal stem cells therapeutics - Mesoblast

Alternative Names: Fucosylated mesenchymal lineage adult stem cells; Fucosylated MLCs

Latest Information Update: 21 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mesoblast
  • Class Stem cell therapies
  • Mechanism of Action Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus

Most Recent Events

  • 17 Mar 2016 Mesoblast in-licenses ex vivo fucosylation technology from Harvard Medical School
  • 17 Mar 2016 Mesoblast has patent protection for the licensed ex vivo fucosylation technology in USA
  • 17 Mar 2016 Preclinical trials in Type-1 diabetes mellitus in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top